EGFR and non-small cell lung carcinoma: This finding suggests that FBXW7 may serve as a potential molecular marker for predicting EGFR‐TKI treatment response and prognosis in NSCLC patients with EGFR mutation and, more importantly, provides a new treatment strategy for these patients.